Review our resources for client conversations.
Help clients understand how our distinct business model funds innovative medical research.
We're always looking for exceptional team members.
By Mike Liss - July 20, 2018
It's one of my favorite quotes from Warren Buffett, the world's most famous value investor: "Price is what you pay; value is what you get."
I'm not sure that it can get any more succinct (or accurate) when it comes to the "growth versus value" conversation, but here's my take: growth obviously has beaten down value in recent years, and irrationally in my estimation. So many good companies are being disregarded in favor of tech—the FAANG stocks (Facebook, Apple, Amazon, Netflix and Google), especially. Sure, I can understand the appeal: you can't beat the feeling of investing in something that seems to keep going up, up and up. But when do the earnings on those names get completely divorced from actual valuations? I don't know the answer to that, but I believe that will happen.
That's just one of the topics I cover in my latest quarterly video. Click play to see what I have to say about trade wars, rising interest rates and inflation.
Looking forward to 2019, we think there’s a great opportunity for small caps to rally again. Sr. Portfolio Manager Jeff John gives three reasons why.
February 20, 2019
Portfolio Manager Jeff Bourke describes how our growth teams are navigating this uncertain environment to find compelling long-term growth opportunities.
February 14, 2019
Learn why we believe high-quality regional bank stocks are attractive entering 2019.
January 31, 2019
While the end of 2018 may have been rocky for financial markets, our value team is excited about their prospects in 2019.
February 6, 2019
Tariffs. Rising rates. Geopolitical turmoil. None of this deters Sr. Portfolio Manager Mike Liss on his mission to turn high-quality companies underperforming into shareholder return. See which industries are on his radar this quarter.
April 17, 2018
Value equity Sr. PM Mike Liss sees good risk-reward opportunities in the energy and pharmaceutical sectors in 2018.
January 05, 2018
Investment return and principal value of security investments will fluctuate. The value at the time of redemption may be more or less than the original cost. Past performance is no guarantee of future results.
References to specific securities are for illustrative purposes only, and are not intended as recommendations to purchase or sell securities. Opinions and estimates offered constitute our judgment and, along with other portfolio data, are subject to change without notice.
The opinions expressed are those of American Century Investments (or the portfolio manager) and are no guarantee of the future performance of any American Century Investments' portfolio. This material has been prepared for educational purposes only. It is not intended to provide, and should not be relied upon for, investment, accounting, legal or tax advice.